SG11202107984RA - Constitutively active chimeric cytokine receptors - Google Patents
Constitutively active chimeric cytokine receptorsInfo
- Publication number
- SG11202107984RA SG11202107984RA SG11202107984RA SG11202107984RA SG11202107984RA SG 11202107984R A SG11202107984R A SG 11202107984RA SG 11202107984R A SG11202107984R A SG 11202107984RA SG 11202107984R A SG11202107984R A SG 11202107984RA SG 11202107984R A SG11202107984R A SG 11202107984RA
- Authority
- SG
- Singapore
- Prior art keywords
- constitutively active
- cytokine receptors
- chimeric cytokine
- active chimeric
- receptors
- Prior art date
Links
- 102000003675 cytokine receptors Human genes 0.000 title 1
- 108010057085 cytokine receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4635—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962812911P | 2019-03-01 | 2019-03-01 | |
US202062980823P | 2020-02-24 | 2020-02-24 | |
PCT/US2020/020415 WO2020180694A1 (en) | 2019-03-01 | 2020-02-28 | Constitutively active chimeric cytokine receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202107984RA true SG11202107984RA (en) | 2021-08-30 |
Family
ID=70057286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202107984RA SG11202107984RA (en) | 2019-03-01 | 2020-02-28 | Constitutively active chimeric cytokine receptors |
Country Status (14)
Country | Link |
---|---|
US (1) | US20200291090A1 (en) |
EP (1) | EP3931207A1 (en) |
JP (1) | JP2022522786A (en) |
KR (1) | KR20210136041A (en) |
CN (1) | CN113508128A (en) |
AU (1) | AU2020232597A1 (en) |
BR (1) | BR112021017365A2 (en) |
CA (1) | CA3129865A1 (en) |
CO (1) | CO2021011198A2 (en) |
IL (1) | IL285939A (en) |
MX (1) | MX2021010443A (en) |
PE (1) | PE20211902A1 (en) |
SG (1) | SG11202107984RA (en) |
WO (1) | WO2020180694A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022522654A (en) | 2019-03-01 | 2022-04-20 | アロジーン セラピューティクス,インコーポレイテッド | Chimeric cytokine receptor carrying PD-1 external domain |
IL295470A (en) | 2020-02-24 | 2022-10-01 | Allogene Therapeutics Inc | Bcma car-t cells with enhanced activities |
AU2021312871A1 (en) | 2020-07-21 | 2023-02-09 | Allogene Therapeutics, Inc. | Chimeric antigen receptors with enhanced signaling and activities and uses thereof |
CA3217252A1 (en) * | 2021-04-19 | 2022-10-27 | Nanjing Legend Biotech Co., Ltd. | Chimeric cytokine receptors and uses thereof in cellular therapies |
WO2023192895A1 (en) | 2022-03-29 | 2023-10-05 | Allogene Therapeutics Inc. | Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
WO2007075899A2 (en) * | 2005-12-21 | 2007-07-05 | Maxygen, Inc. | Dual agonist compounds and uses thereof |
WO2011069004A1 (en) * | 2009-12-04 | 2011-06-09 | Quest Diagnostics Investments Incorporated | Mpl mutations in jak2 v617f negative patients with myeloproliferative disease |
GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
MX2017009181A (en) | 2015-01-26 | 2017-11-22 | Cellectis | ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY. |
PE20171653A1 (en) | 2015-04-13 | 2017-11-13 | Pfizer | CHEMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN |
US20180318303A1 (en) * | 2015-04-15 | 2018-11-08 | Promedior, Inc. | Methods for treating myeloproliferative disorders |
US20190183936A1 (en) * | 2016-08-26 | 2019-06-20 | Baylor College Of Medicine | Constitutively active cytokine receptors for cell therapy |
GB201702617D0 (en) * | 2017-02-17 | 2017-04-05 | Autolus Ltd | Receptor |
KR20200128054A (en) * | 2018-03-02 | 2020-11-11 | 알로젠 테라퓨틱스 인코포레이티드 | Inducible chimeric cytokine receptor |
-
2020
- 2020-02-28 PE PE2021001432A patent/PE20211902A1/en unknown
- 2020-02-28 SG SG11202107984RA patent/SG11202107984RA/en unknown
- 2020-02-28 CA CA3129865A patent/CA3129865A1/en active Pending
- 2020-02-28 KR KR1020217030491A patent/KR20210136041A/en unknown
- 2020-02-28 WO PCT/US2020/020415 patent/WO2020180694A1/en active Application Filing
- 2020-02-28 JP JP2021551799A patent/JP2022522786A/en active Pending
- 2020-02-28 BR BR112021017365A patent/BR112021017365A2/en unknown
- 2020-02-28 EP EP20715579.7A patent/EP3931207A1/en active Pending
- 2020-02-28 US US16/804,917 patent/US20200291090A1/en active Pending
- 2020-02-28 AU AU2020232597A patent/AU2020232597A1/en active Pending
- 2020-02-28 CN CN202080018237.6A patent/CN113508128A/en active Pending
- 2020-02-28 MX MX2021010443A patent/MX2021010443A/en unknown
-
2021
- 2021-08-25 CO CONC2021/0011198A patent/CO2021011198A2/en unknown
- 2021-08-29 IL IL285939A patent/IL285939A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020232597A1 (en) | 2021-08-19 |
JP2022522786A (en) | 2022-04-20 |
MX2021010443A (en) | 2021-12-10 |
CN113508128A (en) | 2021-10-15 |
WO2020180694A1 (en) | 2020-09-10 |
CA3129865A1 (en) | 2020-09-10 |
PE20211902A1 (en) | 2021-09-27 |
CO2021011198A2 (en) | 2021-09-09 |
BR112021017365A2 (en) | 2022-02-01 |
KR20210136041A (en) | 2021-11-16 |
US20200291090A1 (en) | 2020-09-17 |
EP3931207A1 (en) | 2022-01-05 |
IL285939A (en) | 2021-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276831A (en) | Inducible chimeric cytokine receptors | |
IL285939A (en) | Constitutively active chimeric cytokine receptors | |
EP3504223A4 (en) | Constitutively active cytokine receptors for cell therapy | |
IL287407A (en) | Chimeric receptors and methods of use thereof | |
IL285230A (en) | Chimeric cytokine receptors | |
CA205079S (en) | Chair | |
IL279469A (en) | Chimeric growth factor receptors | |
IL291282A (en) | Chimeric cytokine receptors | |
IL281097A (en) | Chimeric antigen receptors against multiple hla-g isoforms | |
GB201905552D0 (en) | Antagonists | |
IL285946A (en) | Selection of t cell receptors | |
IL275079A (en) | Daric interleukin receptors | |
IL285909A (en) | Anti-bcma chimeric antigen receptors | |
GB201801831D0 (en) | Chimeric receptor | |
GB201815629D0 (en) | Antagonists | |
KR102097432B9 (en) | Disposable spuit for delivering fixed quantity | |
GB202115329D0 (en) | Chimeric cytokine receptor | |
CA195359S (en) | Chair | |
CA194017S (en) | Chair | |
GB201910515D0 (en) | GLP-1 Receptor antagonists | |
IL308696A (en) | Nkg2d-based chimeric antgen receptor | |
CA190907S (en) | Chair | |
GB202108364D0 (en) | Chimeric receptor | |
CA189981S (en) | Chair | |
CA187999S (en) | Chair |